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Introduction
Hyperuricemia is defined as a serum uric acid level 
exceeding 6.8 mg/dL (404 μmol/L). At that level we 
can observe a crystallization of a monosodium urate 
in the water solution at the physiological pH and 
body temperature [1–4]. The solubility of the uric 
acid in water and physiologic fluids is limited and de­
pends mostly on the pH and temperature. The solu­
bility in water reaches 6.8 mg/dL (404 μmol/L) at 
the temperature of 37°C. The solubility significantly 
decreases at low temperatures and at acidification 
reaching 6.0 mg/dL (360 μmol/L) at 35°C degrees, 
and only about 4 mg/dL (238 μmol/L) at 30°C 
degrees [2]. Due to this fact,the crystals of the mono­
sodium urate firstly deposit in tissues that are less 
warmed and poorly vascularised (tendons, ligaments) 
or not vascularised (cartilages) e.g. concha, para pe­
ripheral joints regions [1]. In vivo the formation and 
deposition of the urate crystals depends not only on 
the uric acid concentration, pH and temperature, 
but is also regulated by the concentration of the sod­
ium chloride and presence of some connective tissue 
components (probably the fragments of proteogly­
cans). Moreover, it is important to mention that the 
solubility of the uric acid cannot be equated with the 
solubility of its sodium urate (forming the deposits 
in tissues) and depends also on the dissociation of 
both substances. 
The uric acid is a metabolite of purines which 
metabolism influences the development of the hy­
peruricemia.The uric acid is a final product of the 
purines transformation in human and apes while 
in other animals it is further metabolised (catalysed 
by an uricase) to the allantoin, which has high­
er solubility. The evolutionary lack of the uricase 
promotes the development of the higher uric acid 
concentrations in human. Hyperuricemia may re­
sult from the increased production of purines (also 
caused by the intensive lysis of cells), the excessive 
supply (and absorption) of purines and from the 
impaired excretionof the uric acid. Around two 
thirds of the total urates pool in the organism de­
rives from the endogenous production, while the 
remaining one third derives from the consumed 
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dietary purines. About 70% of the produced urates 
is eliminated by the kidneys while the rest is elimi­
nated by the alimentary tract. Hyperuricemia 
results from the overproduction of the uric acid 
(10%) or from the insufficient elimination of the 
uric acid (90%) [2–4].
The recent epidemiologic studies prove, that the 
problem of hyperuricemia and gout concerns many 
millions of people (Fig. 1).
In the nearest future, due to the obesity and me­
tabolic disorders as well as the ageing of the human 
population, one should expect the increasing fre­
quency of hyperuricemia [5, 6]. This phenomenon 
is related to the rapideconomic development and 
change of lifestyle of the society with higher socio­
economic status [7, 8]. An increased prevalence of 
hyperuricemia is favoured by many common, hab­
its, such asmassive consumption of purine rich food 
(meat, giblets, seafood), fructose, alcohol abuse, tak­
ing small doses of aspirin and thiazides. Metabolic 
disorders are a  risk factor for hyperuricemia, and 
around 50% of patients with gout presents concom­
itantly symptoms of a metabolic syndrome. A diag­
nosed gout is closely connected with diabetes, obesi­
ty, coronary disease and arterial hypertension [4, 9, 
10]. A schema of the main risk factors of hyperurice­
mia is presented in Figure 2.
An increased concentration of the uric acid is 
also present in the myeloproliferative and lympho­
proliferative diseases, polycythaemia vera, neoplastic 
diseases, haemolytic anaemia and during the che­
motherapy and radiotherapy treatment (so called 
tumour lysis syndrome) [2].
Figure 1. Prevalence of hyperuricemia in the world  based on NHANES I-III reports (based on: BMC Public Health. 2004; 4: 9; BMC Public  
Health. 2013; 13: 664; Rheum Dis Clin North Am. 2014; 40: 155–175; Ann Rheum Dis. 2014; 73: 1470–1476)
Figure 2. Schematic presentation of the main risk factors of hype-
ruricemia (based on: J Rheumatol. 2000; 27: 1501–1505; Int  
J Cardiol. 2016; 15: 8–14)
Asymptomatic hyperuricemia describes a condition 
of increased concentration of the uric acid [> 6.8 mg% 
(404 μmol/L)] without any symptoms of the gout 
[3]. This condition may last for many years and only 
in a  dozen or so percentage of patients causes the 
development of the gout. 
The relation between hyperuricemia  
and the cardiovascular diseases
It has long been known that the antioxidative pro­
prieties of the uric acid may prevent ageing, oxidative 
stress and cell damage [11–15]. However, the recent 
clinical and epidemiological evidence suggest a nega­
tive influence of the elevated serum concentrations 
of the uric acid. Hyperuricemia plays an important, 
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Tabela I. Diseases of a cardiovascular system and factors asso-
ciated with an increased uric acid concentration (based on: Hyper-
tension. 2006; 47: 962–967; BMC Cardiovascular Disorders. 2016; 
16: 85–98; Int J Cardiol. 2016; 15: 8–14; N Engl J Med. 2008; 359: 
1811–1821; J Cardiol. 2012; 59: 235–242) 
Arterial hypertension and prehypertension 
Kidney diseases (microalbuminuria, reduced glomerular filtration)  
Metabolic syndrome
Obturative sleep apnoea 
Blood vessels diseases (of the jugular, peripheral and coronary arteries)
Stroke and vascular stupor 
Pre-eclampsia 
Increased levels of the acute phase reactanats [C-reactive protein, 
tissue plasminogen activator (PAI) etc.] 




pathophysiological role in the development of the 
arterial hypertension, diabetes mellitus type 2 and is 
an independent cardiovascular risk factor [13–17]. 
The most common cardiovascular diseases and the 
factors related to the increased concentration of the 
uric acid are presented in Table I. 
It is related to a common presence of hyperurice­
mia in persons with the increased cardiovascular risk: 
men, postmenopausal women (oestrogens fosters the 
renal elimination of the uric acid), persons with obe­
sity, arterial hypertension, diabetes, dyslipidaemia 
[3, 18]. Moreover, in patients with arterial hyper­
tension associated with the metabolic syndrome 
a  positive correlation between the serum uric acid 
concentration and a body mass index, fasting insulin 
concentration and the index of the insulin­resistance 
HOMA­IR can be also observed [4]. Hyperuricemia 
is often present in patients with threshold values of 
the blood pressure, especially when it is associated 
with the proteinuria [9, 10, 19].
Lee et al. [19] demonstrated, that patients with 
prehypertension (systolic pressure 120–140 mmHg 
or diastolic pressure 80–90 mmHg) and microal­
buminuria had higher concentrations of the uric 
acid, compared to persons with normal albuminuria 
[males 6.5 ± 1.1 mg/dL (387 ± 65 μmol/L) and to 
6.2 ± 1.1 mg/dL (369 ± 65 μmol/L) respectively; p = 
= 0.017; females 4.8 ± 0.9 mg/dL (286 ± 54 μmol/L) 
vs. 4.4 ± 0.9 mg/dL (262 ± 54 μmol/L); p = 0.006]. 
It was proven in the logistic regression model that, 
having included all cardiovascular risk factors in the 
group of patients with the prehypertension, the high­
er quadrille of the uric acid concentrations was rela­
ted to more than 2 fold higher risk of microalbumi­
nuria occurrence compared to the lowest quadrille in 
both males [odds ratio (OR) 2.12; 95% confidence 
interval (CI) range: 1.16–3.87] and females (OR 
3.36; 95% CI range: 1.17–9.69).
On the basis of the observation of the original 
cohort of the Framigham study, important data con­
firming the predictive value of the uric acid concen­
trations, was acquireds. An increased risk of the coro­
nary disease and cardiac infarction for patients with 
high serum uric acid concentrations was demonstrat­
ed in this study. The mean serum uric concentration 
was 5.0 mg/dL (297 μmol/L) in males and 3.9 mg/ 
/dL (232 μmol/L) in females [16, 20]. 
There is some evidence confirming that in the 
population of patients with a  very high cardiovas­
cular risk, the serum uric acid concentration is an 
independent predictor of mortality. In the study 
published by Ndrepepa et al. [21] a group of 5124 
patients with acute coronary syndromes (1629 heart 
infarctions with ST segment elevation, 1332 without 
ST segment elevation and 2163 with unstable coro­
nary disease) was divided into quartilesaccording to 
the serum uric acid concentrations as follows: quar­
tile 1: 1.3–5.3 mg/dL (77–315 μmol/L); quartile 
2: 5.3–6.3 mg/dL (315–375 μmol/L); quartile 3: 
6.3–7.5 mg/dL (375–446 μmol/L); quartile 4: from 
7.5–18.4 mg/dL (446–1094 μmol/L). After a year 
of observation 80 deaths were recorded in quartile 
1, 77 in quartile 2, 72 in quartile 3 and 122 deaths 
in quartile 4 of the serum uric acid concentrations. 
The uncorrected mortality risk reached 3.05 (95% 
CI 2.54–3.67, p < 0.001) for the fourth quartile vs. 
the first quartile of the uric acid concentrations. It 
is worth mentioning, that the correlation between 
the uric acid concentration and mortality remained 
significant even if the common cardiovascular risk 
factors, kidney function and inflammatory states 
had been included in the analysis (by the increase 
of 12% of the corrected mortality risk per year for 
1 mg/dL (59 μmol/L) of the uric acid). The data is 
shown in Figure 3.
It was also proven that the elevated uric acid 
concentration is not only related to an increased 
risk of the cardiovascular system diseases, but also 
predisposes patients to a  higher incidence of the 
cognitive disorders [22–24]. The results of the epi­
demiological investigation show that hyperuricemia 
may cause dementia [12, 24]. Ruggiero et al. [12] 
in the cross­sectional study of the population of the 
1016 elderly people, evaluated in the multifactor 
logistic regression model the risk of dementia de­
pending on the serum uric acid concentration. The 
study revealed that the patients with dementia had 
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Figure 3. The increase in the uric acid concentration by 1 mg/dL = the increase of the corrected mortality risk per each year by 12% (based 
on: Am J Cardiol. 2012; 109: 1260–1265)
higher serum uric acid concentrations (p = 0.001). 
Moreover, patients with the highest uric acid con­
centrations had threefold (OR = 3.32; 95% CI: 
1.06–10.42) higher probability to develop a  syn­
drome compared to those who were in the lowest 
tercile of the concentrations. 
Pathophysiologic background  
of the influence of hyperuricemia  
on the cardio-vascular system
The dysfunction of the endothelium and the sys­
temic infection are the main two mechanisms which 
impact constituted a basis to explain the effects of the 
hyperuricemia [13, 25]. The inflammatory process 
has a systemic character and is initiated by the crys­
tals of the monosodium urate which are eliminated 
by the phagocytes e.g. neutrophils and macrophages. 
The development of the inflammation is assisted by 
the innate immunity system. The microcrystals are 
coated by opsonising proteins what leads to the acti­
vation of the type 2 and 4 Toll­like receptors and ini­
tiation of the inflammatory process and activation of 
the inflammasome. The pro­inflammatory cytokines 
released by the monocytes and synoviocytes trans­
form the local process into the systemic inflamma­
tion [26]. It is considered that the chronic systemic 
inflammation causes the damage of the endothelium 
of the blood vessels. As a result, the synthesis of the 
nitric oxide is stopped in the vessel wall and the vas­
cular renin­angiotensin system is activated. This leads 
to the hypertrophy of the muscular membrane of the 
vessels (including the proliferation and migration of 
the myocytes) [15]. Besides, the chronic, systemic 
inflammatory process escalates the progress of the 
sclerotic changes [27]. 
One of the main places, in which the antioxidative 
effects of the uric acid occur, is a central nervous sys­
tem, especially in case of coexistence of such medical 
conditions as: multiple sclerosis, Parkinson disease 
or a stroke [28, 29]. The studies suggest that the po­
tential role of the uric acid in prevention of the acute 
activation, by the oxidants, of the pro­inflammatory 
cells in the blood, may be a beneficial mechanism, in 
which the uric acid concentration presents its total 
antioxidative activity. On the other hand, uric acid 
cannot eliminate all oxygenic radicals, such as super­
oxides. Experiments have shown, that, depending on 
the concentration, uric acid may become a pro­oxi­
dant through the activation of the intracellular pro­
duction of the superoxide by the NADP oxidase. It is 
so called the oxidant­antioxidant paradox [30]. The 
uric acid, due to its degradation and aforementioned 
mechanisms, may form the free radicals, what causes 
simultaneously an inflammatory reaction and dys­
function of the endothelium [30, 31]. 
Pharmacological treatment  
of hyperuricemia
Clinical practice in the treatment of the hyperuri­
cemia is a necessity. Another important issue is the 
time when the treatment should be started. Thepaper 
presents a study in which a mathematic model was 
constructed to evaluate two strategies of treatment: 
of all asymptomatic patients with use of allopurinol 
or to start the therapy once the symptoms occur 
(symptomatic treatment). In this model a hypothet­
ic cohort of 50 year old males with different serum 
uric acid concentrations [6.0–6.9 mg/dL (357– 
–410 μmol/L) and 7.0–7.9 mg/dL (416–470 μml/L)] 
were simulated and observed for over 20 years. The 
main end­points of the model were the occurrence of 
the cardiovascular incident and the ratio of mortality 
related with it. In the group of 50 year old males 
with serum uric acid levels 6.0–6.9 mg/dL (357– 
–410 μmol/L), who had received allopurinol indepen ­ 
dently of the symptoms, a 30% decrease of the mean 
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number of cardiovascular incidence and 39% lower 
mortality rate was prognosticated, in comparison to 
the patients treated only with gout symptoms. The 
authors affirmed the presented model was the most 
effective in the prevention of the cardiovascular in­
cidents as long as the treatment when the serum uric 
acid concentration exceeds 7.0 mg/dL (416 μmol/ 
/L) in males and 5.0 mg/dL (297 μmol/L) in females 
[32].
Based on these data, the evaluation of the serum 
uric acid concentrations was included into the rou­
tine tests in the recommendations of both Polish So­
ciety of Arterial Hypertension (Polskie Towarzystwo 
Nadciśnienia Tętniczego, PTNT) in 2011 and 2015 
and European Society Cardiology and European So­
ciety Hypertensiology (ESC/ESH) in 2013 [33–35].
In the cited recommendations the hypotensive 
therapy of patients with coexisting gout should in­
clude sartanes, angiotensin­converting­enzyme in­
hibitors and calcium antagonists. The drugs which 
may increase the concentration of the uric acid, 
mainly thiazide or thiazide­like diuretic and beta­ad­
renolytic are not recommended.
The analysis of the Losartan Intervention for 
Endpoint Reduction (LIFE) study resulted in some 
publications concerning the uricosuric proprieties of 
losartan. These proprieties were due to two mech­
anisms: to the increase of the tubular secretion 
(a  mechanism typical of drugs blocking the RAA 
system) and to the increase of the tubular secretion of 
the uric acid (a mechanism typicalof losartan) [36]. 
These reports resulted in the inclusion of losartan in 
the PTNT 2011 recommendations, as a hypotensive 
drug by choice in the patients with hypertension and 
hyperuricemia [33]. There was no such distinction 
of losartan neither in the ESC/ESH nor American 
recommendations [34, 37]. A  detailed data analy­
sis, the evidence of the unique uricosuric activity of 
losartan seem to be insufficient and not confirmed 
by the EBM proofs. Moreover, losartan, due to its 
short activity time does not meet the actual criteria 
recommending to use the drugs with 24­hours effi­
cacy [35].
In the PTNT 2015 guidelinesthe value of allo­
purinol was emphasized, as a first­line drug in the 
non­hypotensive therapy in patients with arterial 
hypertension and asymptomatic hyperuricemia. 
“Allopurinol, which is used for long­term the­
rapy of gout, may also be considered in hyper­
tensives with asymptomatic hyperuricaemia, par­
ticularly those with cardiovascular disease, due 
to a  proven beneficial effect of this drug on the 
improvement of endothelial function and aortic 
compliance” [35].
Drugs reducing the concentration  
of the uric acid available in Poland
Allopurinol
Allopurinol is a  non­selective xanthine oxidase 
inhibitor, which inhibits synthesis of the uric acid 
dependening on a dose. It is considered to be one 
of the strongestdrugs reducing the serum concentra­
tions of the uric acid [38]. The treatment should be 
initiated by a low dose of 100 mg/day and escalated 
by 100 mg every 2–4 weeks to the maximum dose of 
900 mg/day if necessary. It can be expected, that each 
100 mg of allopurinol will reduce the concentration 
of the uric acid by 1 mg/dL. The drug dose must be 
always adjusted to the creatinine clearance and to 
the concomitant medications used by the patient. 
To obtain a good therapeutic effect the appropriate 
dialy dosing of allopurinol should be applied, i.e. the 
initial dose should equal around 100–200 mg, the 
maintenance dose 300–600 mg and the maximum 
dose 700–900 mg/day [39]. 
A meta­analysis, comparing the allopurinol with 
another drugs reducing the serum concentration 
of uric acid, has been recently published [40]. The 
evidence of the comparable influence on the treat­
ment interruption due to the adverse or severe ad­
verse events as well as on the frequency of the severe 
gout attacks when allopurinol (100–600 mg/day) 
was compared with placebo, benzbromarone (100– 
–200 mg/day) or febuxostate (80 mg/day). Single 
examinations did not report any difference in the 
incidence of the acute gout arthritis (“gout attacks”), 
when allopurinol (300 mg/day) was compared to 
placebo or in the regression of changes caused by the 
urates deposits, when allopurinol (200–300 mg/day) 
was compared to febuxostate (80 mg/day) [41]. 
Allopurinol is commonly used not only due to its 
ability to reduce the concentration of the uric acid, 
but also due to its proven protective impact on the 
cardiovascular system. A beneficial role of allopurinol 
therapy in reducing the mortality was confirmed in 
the study conducted in the population of patients with 
hyperuricemia [serum urates concentration > 7.0 mg/ 
/dL (> 416 μmol/L)]. Patients aged at least 40 years 
were involved in the study. The total death risk was 
compared between the allopurinol treated (n = 2483) 
and untreated patients (n = 7441). Patients in the 
allopurinol treated group had initially worse prog­
nostic factors of death, were characterized by a high­
er body mass index and a  higher frequency of the 
comorbidities. After including the initial uric acid 
concentration, it was proven that the administration 
of allopurinol was related to a decreased total mor­
tality rate by 22% (risk ratio, HR 0.78; 95% CI: 
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0.67–0.91). The results suggesting directly that the 
use of allopurinol may improve the overall survival 
rate in patients with hyperuricemia [42]. 
In another study patients aged ≥ 40 year, with 
diagnosed hyperuricemia (serum uric acid concen­
tration 6.0 mg/dL (> 357 μmol/L) in females and 
7.0 mg/dL (> 416 μmol/L) in males. In the group 
of 5927 patients treated with allopurinol and 5927 
untreated patients, 654 and 718 persons respectively, 
died during the observation period (median = 2.9 
yeas). Allopurinol therapy was involved lower total 
mortality risk (HR 0.89; 95% CI: 0.80–0.99) [43]. 
The above­mentioned dependence seems to result 
from the close relation between the concentration of 
the uric acid and the prevalence of the cardiovascu­
lar diseases. The publication by Agarwal et al. [44] 
supplied some evidence of the beneficial influence 
of allopurinol on reducing the arterial hypertension. 
In the meta­analysis, including 10 clinical studies 
(738 participants), the systolic blood pressure was re­
duced by 3.3 mmHg (95% CI: 1.45–5.3; p = 0.001) and 
the diastolic blood pressure was reduced by 1.3 mmHg 
(95% CI: 0.1–2.5 mmHg; p = 0.03), among pa­
tients receiving allopurinol and the control group 
(untreated). This fact confirms the relation between 
the administration of allopurinol and a  small but 
significant reduction of the blood pressure. The effect 
may be potentially used to optimized the therapy in 
patients with arterial hypertension and coexisting 
hyperuricemia. Comparable conclusions were drown 
from the Chinese meta­analysis in which it was prov­
en that allopurinol reduces the systolic and diastolic 
blood pressure in patients with hyperuricemia [45]. 
Allopurinol also caused an important reduction of 
the systolic blood pressure in patients taking hypo­
tensive drugs as well as in the untreated ones. The 
reduction of the blood pressure may be caused by 
the beneficial effect of allopurinol on the stiffness of 
the arteries and, consequently, on the reduction of 
the cardiovascular complications [46]. The aim of 
another study was to define the relation between the 
concentration of the uric acid and the prevalence and 
the severity of the coronary disease [47]. 705 patient, 
who had undergone coronarography, were involved 
in the study. All participants were evaluated in terms 
of the presence of the cardiovascular risk factors and 
the pharmacotherapy. Before the coronarography the 
serum uric acid concentration was measured in all 
patients. The severity of the coronary disease was 
defined by the SYNTAX scale. The mean concen­
tration of the uric acid was 5.3 ± 1.5 mg/dL (315 ± 
89 μmol/L) in the control group; 5.6 ± 1.4 mg/dL 
(333 ± 84 μmol/L) in the group with mild coronary 
disease; 6.2 ± 1.6 mg/dL (369 ± 95 μmol/L) in the 
group with the moderate coronary disease and 6.5 
± 1.7 mg/dL (387 ± 107 μmol/L) in the group with 
severe form of the disease. The study shown that 
the routing biochemical evaluation of the uric acid 
concentration could be useful in diagnostics of the 
coronary disease. 
Allopurinol therapy, as well as any drugs from 
other groups, is related to the risk of developing 
some side effects. The most common side effects 
are benign skin changes, which occurs in about 2% 
of patients treated by allopurinol. In 0.4% it may 
change into life threatening condition defined as 
a allopurinol hypersensitivity syndrome (AHS). This 
syndrome is characterized by a erythematous, exfo­
liating skin rush, fever, hepatitis and a tubulointer­
stitial nephritis and eosinophilia. The mortality rate 
of this syndromes reaches 25%. It should by stressed 
that not all the typical syndromes must be simulta­
neously present. That is why the occurrence of one 
of them e.g. deterioration of the renal function or 
increase of the transaminase activity should suggest 
the development of AHS. The concomitant use of 
allopurinol with such drugs as: thiazides, ampicillin 
and amoxicillin; is a  risk factor of this potentially 
fatal syndrome [48, 49]. Some experts suggest that 
a decrease glomerular filtration in kidneys may also 
increase the risk of AHS occurrence. Therefore, the 
allopurinol dose, in this group of patients, must be 
adjusted to the glomerular filtration rate [50].
Febuxostat
Another drug which is a  xanthine oxidase inhi­
bitor decreasing the concentration of the serum uric 
acid was recently introduced in Poland [51]. Accor­
ding to the product characteristic, the main indica­
tion for use of febuxostat is a chronic hyperuricemia 
associated with diseases which already resulted in the 
urates deposition (including the gout tubercles and 
active gout inflammation or medical history).
The contraindication are:
 — hypersensitivity to the active substance or to any 
other composite of the medication;
 — patients with coronary disease or with congestive 
heart failure;
 — children and youth under 18 years of age;
 — pregnancy and breast feeding.
The concomitant use of mercaptopurine, azathio­
prine and theophylline is not recommended due to 
the risk of the increased blood levels of these sub­
stances.
The side effects of febuxostat, as well as allopu­
rinol, are rare and have a  mild course. The most 
severe side effects are the cases of severe anaphyla ­ 
xis, including the life threatening Stevens­Johnson 
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syndrome (a toxic, n ecrotic epithelium separation and 
acute anaphylactic reactions) or a drug reaction with 
eosinophilia and systemic syndromes (DRESS) [52].
Summary
The presented data shows that the increased con­
centration of the uric acid, independently of the 
occurrence of the gout syndromes, is associated with 
an increased risk of the development of many cardio­
vascular diseases. The administration of allopurinol 
significantly reduces the serum concentration of the 
uric acid and lowers the risk of cardiovascular disease 
occurrence and of the general mortality. According 
to this data and the unsatisfactory diagnosis and the 
treatment of hyperuricemia, the role of the elevated 
uric acid concentration should be considered as an 
important prognostic factor for patients, especially in 
the prevention of the cardiovascular diseases.
Experts who presenting this opinion suggest that 
the antyuricemic therapy should be administered 
more commonly in Poland and the drug dose ad­
justed to a  patients’ risk and initial uric acid con­
centration. The supplementary data concerning the 
selection process, taking into consideration the indi­
vidualization of treatment, are presented in Table II, 
based on the example of the most popular antiurice­
mic drug — allopurinol. 
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